What is the recommended dose and duration of apixaban (Eliquis) for postoperative venous thromboembolism prophylaxis after total hip arthroplasty, and how should this be documented in the medical record for legal protection?

Apixaban Dosing and Duration for VTE Prophylaxis After Total Hip Arthroplasty

For postoperative VTE prophylaxis after total hip arthroplasty, administer apixaban 2.5 mg orally twice daily starting 12-24 hours after surgery and continue for 35 days (approximately 5 weeks). 1

Dosing Regimen

• Dose: 2.5 mg orally twice daily 1
• First dose timing: 12-24 hours after wound closure (never preoperatively) 1, 2
• Duration: 35 days for hip replacement 1, 3
• Duration: 12 days for knee replacement (if applicable) 1, 3

The FDA label explicitly states this prophylactic dose should begin 12-24 hours postoperatively, which balances thrombosis prevention against surgical bleeding risk. 1 Starting earlier increases perioperative bleeding without improving efficacy. 2

Clinical Evidence Supporting This Regimen

Apixaban demonstrated superior efficacy to enoxaparin in the ADVANCE-3 trial for hip arthroplasty, reducing total VTE or all-cause mortality from 3.9% to 1.4% (relative risk 0.36, P<0.001), with numerically lower bleeding rates. 2 In the ADVANCE-2 knee arthroplasty trial, apixaban reduced VTE from 24.4% to 15.1% compared to enoxaparin 40 mg daily (P<0.0001). 2, 4

The American College of Chest Physicians guidelines suggest LMWH as first-line but recognize apixaban as a reasonable alternative with the advantage of oral administration and no monitoring requirement. 5 Apixaban 2.5 mg twice daily has comparable or superior efficacy to enoxaparin with similar or lower bleeding rates across multiple trials. 2, 5

Documentation for Legal Protection

Essential Elements to Document

Your medical record must include the following components to demonstrate appropriate clinical decision-making:

• Indication: Document "VTE prophylaxis following total hip arthroplasty" with the surgery date 1
• Risk assessment: Note patient-specific VTE risk factors (age, BMI, prior VTE, immobility, cancer) and bleeding risk factors (recent bleeding, thrombocytopenia, concurrent antiplatelet agents, renal function) 5
• Medication details: "Apixaban 2.5 mg orally twice daily, initiated [date/time] at [X] hours post-surgery, to continue for 35 days" 1
• Patient counseling: Document discussion of bleeding signs/symptoms (unusual bruising, blood in urine/stool, severe headache), missed dose instructions, and when to seek emergency care 1
• Contraindications reviewed: Document absence of active pathological bleeding, severe hypersensitivity, and appropriate renal function (apixaban is contraindicated if CrCl <15 mL/min) 1
• Drug interactions assessed: Document review of concomitant medications, particularly strong dual CYP3A4 and P-glycoprotein inhibitors (ketoconazole, ritonavir) which are contraindicated 2, 1
• Follow-up plan: Specify when prophylaxis ends (35 days post-surgery) and plan for reassessment if complications arise 1

Sample Documentation Template

"Patient underwent total hip arthroplasty on [date]. VTE risk factors include [list factors]. Bleeding risk assessed as low/moderate [specify]. Initiated apixaban 2.5 mg PO BID at [time], which is [X] hours post-surgery, per FDA-approved dosing for VTE prophylaxis. Plan 35-day course ending [date]. Patient counseled on bleeding precautions, signs/symptoms requiring immediate evaluation, and importance of adherence. No contraindications identified. Renal function adequate (CrCl [value]). No interacting medications. Patient verbalized understanding."

Common Pitfalls to Avoid

• Do not start apixaban preoperatively – this increases surgical bleeding risk without benefit 1, 2
• Do not use therapeutic doses (5 mg or 10 mg BID) for routine prophylaxis – the prophylactic dose is specifically 2.5 mg BID 1
• Do not stop at 10-14 days for hip replacement – the evidence-based duration is 35 days, not the shorter knee replacement duration 1, 2
• Do not combine with therapeutic-dose LMWH – overlapping full anticoagulation increases bleeding risk 6
• Do not use in severe renal impairment (CrCl <15 mL/min) – apixaban is contraindicated 1

Special Considerations

If the patient was on chronic anticoagulation preoperatively (e.g., for atrial fibrillation), the perioperative management differs from prophylaxis-only patients. For high-bleeding-risk surgery like hip arthroplasty, stop apixaban 48 hours (2 days) before surgery. 7, 1 Resume therapeutic dosing 48-72 hours postoperatively once hemostasis is secure, not the prophylactic 2.5 mg dose. 7

Bridging with heparin is not recommended when interrupting apixaban perioperatively due to its rapid offset (half-life 8-14 hours) and rapid onset. 6, 3 The only exception is patients at very high thrombotic risk, though this is rarely applicable in elective arthroplasty. 3

Monitor renal function postoperatively if the surgical procedure or patient's medical condition could affect kidney function, as apixaban dosing depends on creatinine clearance. 6

Comparison with Alternative Agents

Recent real-world data from 2018-2023 showed aspirin may have lower rates of VTE and bleeding complications than apixaban after hip and knee arthroplasty, though this contradicts earlier randomized trial data. 8 However, the CHEST guidelines and FDA approval support apixaban as superior to aspirin for VTE prevention. 5, 1 The choice between agents should consider individual patient factors, with aspirin reserved for lower-risk patients per shared decision-making. 9

Apixaban offers advantages over LMWH including oral administration, no injections, no monitoring requirement, and proven efficacy. 2, 5 It is preferred over warfarin due to predictable pharmacokinetics, no INR monitoring, fewer drug interactions, and similar or superior efficacy with less bleeding. 5